Desjardins Reaffirms Buy Rating for TSO3 Inc. (TOS)

Desjardins reissued their buy rating on shares of TSO3 Inc. (TSE:TOS) in a research report sent to investors on Wednesday. They currently have a C$4.00 price target on the stock. Desjardins also issued estimates for TSO3’s Q3 2017 earnings at ($0.03) EPS, Q4 2017 earnings at ($0.03) EPS, FY2017 earnings at ($0.11) EPS, FY2018 earnings at ($0.08) EPS and FY2019 earnings at $0.01 EPS.

A number of other equities analysts have also issued reports on TOS. Canaccord Genuity reissued a buy rating and set a C$5.25 price target on shares of TSO3 in a research report on Monday, June 26th. Scotiabank reissued an outperform rating and set a C$4.50 price target on shares of TSO3 in a research report on Thursday, July 6th.

Shares of TSO3 (TOS) opened at 2.69 on Wednesday. TSO3 has a 12 month low of $2.05 and a 12 month high of $3.69. The company’s 50-day moving average is $2.64 and its 200 day moving average is $2.89. The company’s market capitalization is $249.48 million.

TRADEMARK VIOLATION NOTICE: “Desjardins Reaffirms Buy Rating for TSO3 Inc. (TOS)” was originally posted by Stock Observer and is owned by of Stock Observer. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at

In other news, Director Richard Mark Rumble acquired 22,000 shares of the company’s stock in a transaction dated Wednesday, August 23rd. The shares were acquired at an average price of C$2.23 per share, with a total value of C$49,060.00.

TSO3 Company Profile

TSO3 Inc is a Canada-based company engaged in the sale, production, maintenance, research, development and licensing of sterilization processes, related consumable supplies and accessories for heat-sensitive medical devices. The Company designs products for sterile processing areas in the hospital environment.

Receive News & Ratings for TSO3 Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TSO3 Inc. and related companies with's FREE daily email newsletter.

Leave a Reply